Expression of fibronectin splice variants in the postischemic rat kidney

Anna Zuk1,2, Joseph V. Bonventre3,4,5, and Karl S. Matlin1,2

1 Department of Surgery, Beth Israel Deaconess Medical Center, Boston 02215; Departments of 2 Surgery and 3 Medicine, Harvard Medical School, Boston 02115; 4 Medical Services, Massachusetts General Hospital, Charlestown 02129; and 5 Division of Health Sciences and Technology, Harvard Medical School-Massachusetts Institute of Technology, Cambridge, Massachusetts 02139


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Using an in vivo rat model of unilateral renal ischemia, we previously showed that the expression and distribution of fibronectin (FN), a major glycoprotein of plasma and the extracellular matrix, dramatically changes in response to ischemia-reperfusion. In the distal nephron in particular, FN accumulates in tubular lumens, where it may contribute to obstruction. In the present study, we examine whether the tubular FN is the plasma or cellular form, each of which is produced by alternative splicing of a single gene transcript. We demonstrate that FN in tubular lumens does not contain the extra type III A (EIIIA) and/or the extra type III B (EIIIB) region, both of which are unique to cellular FN. It does, however, contain the V95 region, which in the rat is a component of FNs in both plasma and the extracellular matrix. Expression of FN containing EIIIA increases dramatically in the renal interstitium after ischemic injury and continues to be produced at high levels 6 wk later. V95-containing FN also increases in the interstitial space, albeit more slowly and at lower levels than FN containing EIIIA; it also persists 6 wk later. FN containing the EIIIB region is not expressed in the injured kidney. The presence of V95 but not the EIIIA or EIIIB regions of FN in tubular lumens identifies the origin of FN in this location as the plasma; tubular FN is ultimately voided in the urine. The data indicate that both plasma and cellular FNs containing the V95 and/or EIIIA regions may contribute to the pathogenesis of acute renal failure and to the repair of the injured kidney.

alternative splicing; extracellular matrix; renal injury; regeneration; acute renal failure


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

FIBRONECTINS (FNs) ARE A FAMILY of large (~440 kDa) dimeric glycoproteins implicated in a variety of biological processes, including tissue remodeling during wound healing and embryonic development (for review, see Refs. 29, 40). FNs influence these processes by affecting cell adhesion and extracellular matrix assembly. They exist in two forms, plasma and cellular. Plasma FN is made by hepatocytes and circulates in the blood; cellular FN is produced by epithelial and connective tissue cells and is deposited into the extracellular matrix. Both forms of FN are encoded by a single gene, whose transcript can be alternatively spliced at three intron-exon boundaries, yielding FN protein subunits containing, in the rat, the extra type III A (EIIIA) repeat, the extra type III B (EIIIB) repeat, and/or the variable (V) region (Fig. 1; for review, see 19, 51-52). Equivalent regions in humans are designated EDA, EDB, and IIICS. During splicing of FN mRNA, these exons are either included or excluded depending on the tissue and cell type. In plasma FN mRNA, exons encoding the EIIIA and EIIIB segments are excluded, whereas the exon encoding the V region is either partially or completely included depending on the species. In cellular FN mRNA, EIIIA and/or EIIIB exons are wholly retained and the V region appears to be at least partially included (43, 45, 56). Up to 12 different combinations of the three alternatively spliced segments are possible, resulting in a heterogeneous mixture of FN isoforms (32, 53).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic illustration of 1 subunit of a fibronectin (FN) dimer in the rat. FN consists of a series of type I, II, and III repeats, each of which is specialized into binding domains with affinities for fibrin, collagen, cells, and heparin. The role of the first seven type III repeats (III, 1-7) is incompletely understood. The EIIIB and EIIIA (extra type III, A and B) repeats that are produced by alternative splicing of mRNA are darkened. The V120 region that is also alternatively spliced is illustrated by a rectangle with shaded (V25) and hatched (V95) areas. An arginine-glycine-aspartic acid (RGD) sequence present in the cell binding domain and a PEILDV sequence in V25 interact with the alpha 5beta 1 and alpha 4beta 1 integrins, respectively. Arginine-arginine (RR) in the heparin domain mediates binding to heparin. The synergistic site (brackets) in cooperation with RGD promotes full cell spreading [redrawn from Schwarzbauer (51)].

The function of the various isoforms is incompletely understood. FNs retaining the EIIIA and/or EIIIB regions are widely expressed in embryonic tissues and cultured cell lines compared with normal adult tissues (12, 20-21, 43-44, 46-47, 53, 64). Upregulation of EIIIA- and/or EIIIB-containing FN has also been noted in the adult at sites of tissue injury, such as in the skin (14, 22), eye (41, 67), and vasculature (17, 25, 28, 60). Isoforms containing a subsegment of the V region known as V25 are also preferentially expressed in embryos and injured peripheral nerves (37, 68).

In the kidney, FN isoforms are differentially expressed during development. In human fetal kidney, FN containing the EDA segment is widely found in tubular and glomerular basement membranes, the interstitium, and glomerular mesangium (34). The isoform containing the EDB region follows a similar but more restricted distribution, localizing to the mesangium, the interstitium, and basement membranes of medullary tubules and collecting ducts, albeit at lower levels (34). In the adult human nephron, FN containing EDA is found only in the mesangium; neither EDA- nor EDB-containing FNs are detected in tubular basement membranes or the interstitial compartment (34).

We previously demonstrated in an in vivo model of unilateral renal ischemia that FN strongly increases in expression and changes its distribution in response to injury (76). In particular, high concentrations of FN were observed in tubular lumens, suggesting a possible role in tubular obstruction. This study was initiated to understand whether tubular FN originated from plasma or from epithelial and/or connective tissue cells after ischemic injury. We demonstrate that luminal FN originates from plasma and is voided in the urine. We also observe that in response to ischemia-reperfusion, FN containing the EIIIA and/or V segments dramatically increases and V-FN, in particular, changes its distribution. These observations have important implications for understanding the mechanism(s) involved in the pathophysiology of acute renal failure (26, 62).


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Surgical procedure. A unilateral rat model of renal ischemia in which the renal artery and vein are clamped for 40 min whereas the contralateral kidney is left intact was used in this study.

Male Sprague-Dawley rats (190-275; Charles River Breeding Laboratories, Wilmington, MA) were housed for 6 days before surgery in the animal facility under alternating cycles of 12 h light, 12 h dark. Water and rat chow were administered ad libitum. In preparation for surgery involving unilateral renal ischemia without removal of the contralateral kidney, animals were weighed and 5-10 ml of sterile saline at 37°C were injected intraperitoneally. Animals were then anesthesized with pentobarbital sodium (6.5 mg/100 g; Abbott Laboratories, North Chicago, IL), and shaved over the left flank. Each was positioned on a warm operating platform (Homeothermic Control Unit; Harvard Apparatus, Holliston, MA) maintained at 37°C, and an incision was made over the left flank region. The renal artery, vein, and ureter were dissected free of surrounding tissue; only the renal artery and vein were clamped with a microaneurysm clamp (Roboz Surgical Instruments, Washington, DC). The incision was temporarily closed, and the animal was placed in an enclosed chamber at 37°C (Small Animal Intensive Care Unit, Harvard Apparatus). After 40 min, the clamp was removed, allowing the kidney to be reperfused with blood. The incision was then permanently sutured, and, after recovery, animals were placed in metabolic cages (Nalgene Labware, Rochester, NY). At the stated times after reperfusion, both kidneys (left postischemic and right contralateral) were either fixed in situ for immunocytochemistry or excised and frozen in liquid nitrogen for biochemistry (see Tissue harvesting). Some animals underwent sham surgery without ischemia. For sham surgery, in lieu of clamping the renal artery and vein, the left kidney was surgically exposed and gently manipulated.

In the unilateral model of renal ischemia, there are only mild systemic changes in blood urea nitrogen and creatinine because of the presence of the intact contralateral kidney (36, 72).

Urine collection. Urine was collected at 24-h intervals in the presence of Complete protease inhibitors (Boehringer-Mannheim, Indianapolis, IN) from animals housed in metabolic cages (100 µl of 50× protease inhibitor/collection tube). The volume collected was measured, and the urine was filtered through two layers of cheesecloth before being centrifuged at 2,000 rpm at 0°C for 30 min. Urine was then filtered through a 0.45-µm Millex-HA filter (Millipore, Bedford, MA), aliquoted, and frozen in liquid nitrogen. Samples were stored at -80°C.

Tissue harvesting. Animals were anesthetized before tissue harvesting. For immunocytochemistry, rats were perfused through the left ventricle with warm Hanks' balanced salt solution and then with 2% paraformaldehyde-75 mM L-lysine-10 mM sodium periodate (PLP; 38). Kidneys were removed and stored intact in fixative overnight at 4°C. They were then rinsed in PBS and stored in PBS containing 0.02% sodium azide at 4°C.

For biochemical analysis, rats were perfused through the left ventricle with sterile PBS (Dulbecco's formulation) at 0°C containing 0.16× complete protease inhibitors (Boehringer-Mannheim). Kidneys were removed, placed on ice, and dissected free of adherent connective tissue. Slices were cut, extending from the cortex to the hilus, frozen in liquid nitrogen, and stored at -80°C.

Antibodies. A variety of monoclonal and polyclonal antibodies against FN were used in this study. Rabbit anti-rat FN polyclonal antibody (GIBCO-BRL, Grand Island, NY) was generated against rat plasma FN. This antibody recognizes regions of the FN molecule that are common to both the plasma and cellular forms. It was used to detect all forms of FN in tissue sections (1:750) and immunoblots (1:7,500). It is therefore referred to as anti-total FN antibody. Specificity of the anti-total FN antibody was determined by competition experiments between the antibody and purified antigen (76). Briefly, the anti-total FN antibody was incubated with purified rat plasma fibronectin, and the mixture then applied to tissue sections. After rinsing, sections were processed as described below for immunocytochemistry. Under these conditions, immunostaining was obliterated (76).

Culture supernatant containing mouse monoclonal antibody against the EDA region of human cellular FN was obtained from I. Virtanen (Univ. of Helsinki, Helsinki, Finland; 64). Alternatively, the same purified antibody was purchased from Chemicon International (Temecula, CA). This antibody specifically recognizes the extra domain of human cellular FN (EDA sequence) but also cross-reacts with the rat EIIIA region (Chemicon International; see also Figs. 5-7). Culture supernatant was used undiluted for immunofluorescence whereas purified antibody was used at a 1:1,000 dilution to immunoblot kidney tissue extracts and urine. Rabbit polyclonal antibody R2640 to the rat EIIIB segment was obtained from R. O. Hynes (46, 47) and used at a 1:100 dilution. This antibody recognizes the EIIIB segment in the context of a bacterial fusion protein because the immunogen was an EIIIB-glutathione S-transferase fusion protein. In order for this antibody to recognize EIIIB in mammalian cells, N-linked carbohydrate was removed from target FN by pretreating tissue sections overnight with N-glycanase (46, 47; see cryosectioning and immunofluorescence). Rabbit polyclonal antibody 73N recognizing the V95 region of FN was also obtained from R. O. Hynes (46, 47) and was used at a dilution of 1:100 for immunocytochemistry. This region is one of three variants of the V segment found in rat (V120, V95, and V0). Both the rabbit polyclonal antibody R2640 to the rat EIIIB segment and rabbit polyclonal antibody 73N to the V95 region of FN are suitable for immunocytochemistry (7, 42, 46, 47) and not biochemistry. These antibodies have been used for studies in the kidney (7, 42, 46).

Cryosectioning and immunofluorescence. For frozen sections, fixed intact kidneys were sliced and equilibrated overnight at 4°C in 0.6 M sucrose/PBS. Kidney slices were then embedded in OCT (optimal cutting temperature) compound (Miles Laboratories, Naperville IL) and frozen in liquid nitrogen. Sections (5 µm) were cut on either a Reichert Frigocut cryostat (Leica, Deerfield, IL) or a Leica CM1850 cryostat. Sections were placed on SuperFrost Plus glass slides (Fisher Scientific, Boston, MA) and stored at -20°C until use.

For immunostaining, the procedure of Zuk et al. (76) was used. Briefly, sections were fixed to the slides by incubating in PLP followed by washing in PBS. Autofluorescence was then quenched with sodium borohydride/PBS (1 mg/ml). After washing, sections were permeabilized with 0.1% Triton X-100/PBS and washed again. To immunostain the rat EIIIB segment, tissue sections were enzymatically digested with N-glycanase (50,000 units/ml; New England Biolabs, Beverly, MA) at 37°C overnight (46, 47). Nonspecific binding sites were then blocked with 10% normal goat serum. Sections were incubated in primary antibody overnight at 4°C followed by washing and incubation in secondary antibody. These antibodies were either goat anti-rabbit FITC adsorbed against mouse and human Ig (1:200; BioSource International, Camarillo, CA) or goat anti-mouse indocarbocyanine (CY3) adsorbed against rat, human, bovine, and horse serum proteins (1:800; Jackson ImmunoResearch Laboratories). Sections were washed, mounted in VectaShield (Vector Laboratories, Burlingame, CA) and viewed on a Zeiss Axoplan, Axiophot, or Axiovert microscope (Carl Zeiss, Thornwood, NY). Images were recorded on TMAX 400 film (Eastman Kodak, Rochester, NY) at ASA 800.

Controls for immunostaining included omitting the primary and/or secondary antibody and immunostaining tissue sections known to contain the antigen of interest. In all cases, kidney sections serving as control were from the same animal and time point (ischemic, contralateral or sham-operated kidney). Immunostaining was repeated at least three times on sections from at least two animals for each time point and condition.

Fluorescence staining intensity was subjectively graded as follows: (---), absent; (+), faint; (++), moderate; and (+++), strong. These grades pertain to the overall intensity of staining within the tissue, rather than to a particular structure within it. Tissue staining patterns produced by the anti-total and anti-segment-specific antibodies include: B, basement membrane zone; I, renal interstitium; L, tubular lumen of the distal nephron; and C, renal corpuscle.

Western Blotting

Immunoblotting was repeated at least three times with samples from a minimum of two animals for each time point and condition.

Tissue samples. Frozen kidney tissue was quickly weighed and transferred to a Dounce homogenizer on ice. Nine parts 2× sample buffer (400 mM Tris, pH 8.8, 10 mM EDTA, 2% SDS) at 4°C containing protease inhibitors (10 µg/ml aprotinin, 1 µg/ml antipain, 1 µg/ml pepstatin, 17.5 µg/ml benzamidine) but lacking sucrose, bromophenol blue and dithiothreitol (DTT) were then added. Tissue was extensively homogenized and boiled for a total of 8 min at 95°C to completely solubilize cell proteins. Samples were then cooled to room temperature, DTT was added to 40 mM, and samples were further homogenized and boiled (4 min). After cooling to room temperature, samples were sheared in succession with 22-, 23-, and 26-gauge needles, transferred to microfuge tubes, and spun twice at 16,000 g for 5 min at room temperature. Any remaining pellet was reextracted (2× sample buffer containing DTT, SDS, and protease inhibitors), sheared, and centrifuged as before. Supernatants were pooled, and protein concentration was then measured using the Standard Bio-Rad Protein Assay (Bio-Rad, Hercules, CA) with BSA as standard.

Urine samples. Urine samples were thawed on ice for 15-20 min and centrifuged for 5 min at 4°C. Typically, no pellet was visible. Volumes of urine containing equivalent amounts of protein were mixed with an equal volume of 2× sample buffer containing 24% sucrose, 0.2% bromophenol blue, 40 mM DTT and protease inhibitors. Samples were boiled at 95°C for 4 min and quickly cooled on ice.

Tissue and urine samples were further diluted with 1× sample buffer (200 mM Tris, pH 8.8, 5 mM EDTA, 12% sucrose, 0.1% bromophenol blue, 20 mM DTT, 2% SDS) without protease inhibitors to yield aliquots of protein suitable for gel loading. They were then boiled again, cooled, alkylated with 0.5 M iodoacetamide in the dark at 37°C for 20 min, and either frozen in liquid nitrogen and stored at -80°C or used immediately.

Samples were resolved by 6% SDS-PAGE (33). For immunoblotting, gels were equilibrated in transfer buffer (20% methanol, 48 mM Tris, 0.038% SDS, 39 mM glycine) for 20 min, and proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (Immobilin-P, Millipore) at 90 mA for 72 min. To confirm equal transfer of proteins, membranes were stained with Coomassie blue and then destained. Membranes were washed with 10 mM Tris, pH 7.5, 100 mM NaCl, and 0.1% Tween 20, blocked in 5% nonfat dry milk in wash buffer, and incubated in primary antibody overnight at 4°C with rotation. Membranes were washed extensively, reacted with secondary antibody conjugated to horseradish peroxidase (HRP; donkey anti-rabbit HRP or donkey anti-mouse HRP; Jackson ImmunoResearch Laboratories, Westgrove, PA) for 1 h at room temperature, and washed again. HRP was reacted with either 0.05% diaminobenzidine (Sigma, St. Louis, MO) or Renaissance chemiluminescence reagents (NEN Life Science Products, Boston, MA). For the latter, membranes were exposed to either X-OMAT Blue (Eastman Kodak) or Reflection (DuPont-NEN) autoradiography films. Films were developed with a Kodak X-OMAT processor.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We and others have previously demonstrated in in vivo rat models of renal ischemia that cell extracellular matrix interactions dynamically change in response to injury (70, 76). In particular, we demonstrated that FN, a major glycoprotein of the plasma and renal interstitium, significantly altered its distribution and expression. Most surprisingly, it was intensely immunostained in tubular lumens. In this location, FN might contribute to tubular obstruction, a major outcome of renal artery occlusion and reperfusion. Because our earlier work did not distinguish among the various forms of FN, we were unable to determine whether lumenal FN originated from leakage of plasma proteins or from the synthesis and deposition of the cellular form by tubular epithelial or connective tissue cells. Resolution of this issue is important for our understanding of how FN is involved in the pathogenesis of ischemic renal injury. To investigate the source of luminal FN, polyclonal and monoclonal antibodies against specific regions of this molecule that are found in either plasma and/or cellular FNs (EIIIA, EIIIB, and V95) were used to determine the distribution of plasma and cellular FNs in response to ischemia reperfusion.

Distribution and Expression of FN in the Outer and Inner Stripes

Total FN. Using a polyclonal antibody that recognizes both plasma and cellular FNs, referred to as anti-total FN antibody, FN was immunolocalized in kidney sections of rats killed at various times after reperfusion after a 40-min unilateral clamp of the renal artery and vein. In kidneys made ischemic but not reperfused (0 h postischemia, Fig. 2, A and B), anti-total FN antibody outlines tubules in the outer stripe (Fig. 2A) and inner stripe (Fig. 2B); it also stains the interstitial space (Figs. 2, A and B). One to three hours after reperfusion, localization is maintained (outer stripe, Fig. 2C; inner stripe, Fig. 2D). However, anti total-FN antibody also stains the luminal space of some tubules of the thick ascending limb in the inner stripe (asterisks, Fig. 2D).


View larger version (162K):
[in this window]
[in a new window]
 
Fig. 2.   Immunofluorescent staining of cryostat sections of postischemic kidneys reacted with the polyclonal total FN antibody recognizing both the plasma and cellular forms. A, C, E, and G represent the outer stripe of the outer medulla; B, D, F, and H represent the inner stripe of the outer medulla. At 0 h postischemia (A-B), total FN localizes to the interstitium surrounding basement membranes of S3 proximal tubules in the outer stripe (A) and thick ascending limbs in the inner stripe (B). At 3 h postischemia (C-D), total FN continues to localize to these regions; however, in the outer stripe (C), it also highlights broken basement membrane (arrow). In the inner stripe (D), it is detected in a few tubular lumens (asterisks). At 24 h postischemia (E-F), interstitial staining for total FN increases. The frequency of tubular FN is also greater within lumens of the outer (E) and inner (F) stripes (asterisks). By 120 h postischemia (G-H), luminal FN is not detected in the outer (G) or inner (H) stripes; however, interstitial FN staining remains strong. The faint apical staining in G is nonspecific. Bar = 40 µm.

At 24-48 h after reperfusion, total FN immunostaining increases, strongly outlining the perimeter of tubules in both the outer and inner stripes and localizing in a fibrillar pattern to the interstitial compartment. In the outer stripe (Fig. 2E), where injury is most evident (16, 24, 50), diffuse total FN staining is observed in the lumens of S3 proximal tubules (asterisks, Fig. 2E). Staining of total FN within tubular spaces of other nephron segments coursing through this region is absent at this time (76). Most interestingly, in the inner stripe of the outer medulla, strong FN immunoreactivity is detected in the lumen of many tubules of the thick ascending limb (asterisks, Fig. 2F; 76).

By 120 h after reperfusion, total FN is absent from tubular lumens of proximal S3 (Fig. 2G) and distal nephron segments (Fig. 2H). However, it continues to be strongly expressed in a fibrillar pattern in an expanded interstitium in the outer (Fig. 2G) and inner (Fig. 2H) stripes.

In normal (76), contralateral, and mock-operated (mock) kidneys at all time points, anti-total FN antibody outlines tubules in the outer and inner stripe; it also stains the interstitial space (for contralateral outer and inner stripes at 24 h, see Fig. 3, A and B, respectively; for mock outer and inner stripes at 24 h, see Fig. 3, E and F, respectively; for contralateral outer and inner stripes at 120 h, see Fig. 3, C and D, respectively; for mock outer and inner stripes at 120 h, see Fig. 3, G and H, respectively; data not shown for contralateral and mock kidneys at 0 and 3 h). Contrary to that observed in postischemic animals, total FN does not localize to tubular lumens of S3 segments in the outer stripe at any time (compare 24 h postischemic, Fig. 2E to 24 h contralateral and mock, Fig. 3, A and E, respectively). It also does not localize to the luminal space of thick ascending limbs in the inner stripe (compare 24 h postischemic, Fig. 2F to 24 h contralateral and mock, Fig. 3, B and F, respectively). In addition, contrary to that observed in the ischemic kidney after reperfusion (see Fig. 2, C-H), interstitial staining does not change; the connective tissue compartment does not enlarge in either contralateral (see 24 and 120 h, Fig. 3, A-B and Fig. 3, C-D, respectively) or mock kidneys (see 24 and 120 h, Fig. 3, E-F and Fig. 3, G-H, respectively) and always resembles the 0-h time point of the postischemic kidney (see Fig. 2, A and B).


View larger version (131K):
[in this window]
[in a new window]
 
Fig. 3.   Immunofluorescent staining of cryostat sections of contralateral (A-D) and mock (E-H) kidneys reacted with polyclonal total FN antibody. A, C, E, and G represent the outer stripe of the outer medulla; B, D, F, and H represent the inner stripe of the outer medulla. The 24-h time point is demonstrated in A-B and E-F whereas the 120-h time point is shown in C-D and G-H. Total FN localizes to the interstitium and surrounds basement membranes of S3 proximal tubules in the outer stripe and thick limbs in the inner stripe. It is not detected in tubular lumens at 24 h (A-B and E-F), nor does interstitial staining increase at 120 h (C-D and G-H). Bar = 28 µm.

Immunoblotting of kidney extracts confirms the increase in total FN in response to ischemic reperfusion injury (Fig. 4A). Total FN increases from 24 to 120 h in postischemic kidneys (Fig. 4A) but not in contralateral (Fig. 4B) or mock (Fig. 4C) kidney tissue.


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 4.   Immunoblot of kidney tissue (10 µg/lane) after 6% SDS-PAGE probed with polyclonal total FN antibody and donkey anti-rabbit horseradish peroxidase (HRP); HRP was visualized with diaminobenzidine. Total FN (220 kDa under reducing conditions) significantly increases from 24 to 120 h in postischemic kidneys (A) compared with contralateral (B) and mock (C) kidney tissue. Purified plasma FN (10 ng/lane) served as positive control (+C).

The accumulation of FN identified with the anti-total FN antibody in tubular lumens and interstitial compartments raised the question of which form, plasma and/or cellular, localized to these regions. Immunolocalization of the EIIIA segment unique to cellular FN was first examined using a monoclonal antibody generated against the human EDA site that cross-reacts with rat EIIIA.

EIIIA-FN. At 0 h postischemia, FN containing the EIIIA segment is not detected in the outer (Fig. 5A) or inner stripes (Fig. 5B) of the outer medulla. Rarely, some patchy, faint immunostaining associated with tubular basement membranes is observed (arrow, Fig. 5A); red blood cells also autofluoresce at this time (asterisks; Fig. 5, A and B). Production of EIIIA-FN significantly increases 1-3 h after reperfusion, associating primarily with basement membranes of S3 proximal tubules in the outer stripe (Fig. 5C) and thick limbs of the inner stripe (Fig. 5D). Interstitial localization in the inner stripe is also strong. FN containing the EIIIA segment is not detected in tubular lumens of the inner stripe (Fig. 5D), in contrast to the observation with anti-total FN antibody (Fig. 2D).


View larger version (141K):
[in this window]
[in a new window]
 
Fig. 5.   Immunofluorescent staining of cryostat sections of postischemic kidneys reacted with monoclonal antibody recognizing the EIIIA region of cellular FN. A, C, E, and G represent the outer stripe of the outer medulla; B, D, F, and H represent the inner stripe of the outer medulla. At 0 h reperfusion (A-B), the EIIIA region of cellular FN is not detected in the outer (A) or inner (B) stripes. A few tubules, however, demonstrate a faint patchy distribution (arrows, A). Note the autofluorescence of red blood cells (asterisks, A-B). At 3 h reperfusion (C-D), FN containing EIIIA is detected at high levels in the interstitial space between S3 proximal tubules in the outer stripe (C) and thick limbs in the inner stripe (D), where it outlines tubular basement membranes. At 24 h reperfusion (E-F), staining for EIIIA-FN further increases, especially in the outer stripe (E), where the interstitial space appears enlarged. At 120 h after reperfusion (G-H), EIIIA-FN persists at high levels in an expanded interstitium in both the outer (G) and inner (H) stripes, suggesting an incipient fibrosis. Note that at 3 and 24 h after reperfusion, FN containing EIIIA is not detected in tubular lumens. Bar = 40 µm.

At 24 and 48 h after ischemia-reperfusion injury, a further increase in immunostaining for EIIIA-FN in the outer and inner stripes is observed. FN containing EIIIA associates with both the interstitial matrix and renal basement membrane (outer stripe, Fig. 5E and inner stripe, Fig. 5F). In the outer stripe especially (Fig. 5 E), the interstitial space appears enlarged. EIIIA-FN is absent from tubular lumens in the outer (Fig. 5E) and inner stripes (Fig. 5F), in contrast to the presence of total FN in this location at this time (see Fig. 2, E and F for outer and inner stripes, respectively). At 120 h after reperfusion, strong reactivity for FN containing EIIIA persists in an expanded interstitial matrix (outer stripe, Fig. 5G and inner stripe, Fig. 5H), consistent with previous observations (9). Again, none is found in the luminal space (outer stripe, Fig. 5G and inner stripe, Fig. 5H).

In contralateral kidneys at 0 h, EIIIA-FN is rarely detected in the outer medulla (data not shown), similar to that observed in the postischemic kidney at this time point (see Fig. 5, A and B). However, at 1-3 h, FN containing EIIIA begins to be associated with the renal interstitium and basement membrane of tubules in the outer (Fig. 6A) and inner (Fig. 6B) stripe, reminiscent of the staining pattern observed in the 1-3 h postischemic kidney (compare Fig. 6, A and B, with Fig. 5, C and D). Localization does not change in contralateral kidneys at 24, 48, and 120 h; EIIIA-FN continues to be found in the interstitium, associating with basement membranes of tubules in the outer (24 h, Fig. 6C) and inner (24 h, Fig. 6D) stripes (data not shown for 48 and 120 h). Immunostaining, however, is not as intense at these times compared with the corresponding postischemic kidney (for 24 h, compare Fig. 6, C and D to Fig. 5, E and F). In mock animals, FN containing EIIIA is absent or rarely detected in the outer stripe at all time points (for 24 and 120 h, see Fig. 6, E and G, respectively; data not shown for 0 and 3 h); infrequently, some faint immunostaining is seen in the inner stripe (for 24 and 120 h, see arrows Fig. 6, F and H, respectively; data not shown for 0 and 3 h).


View larger version (106K):
[in this window]
[in a new window]
 
Fig. 6.   Immunofluorescent staining of cryostat sections of contralateral (A-D) and mock (E-H) kidneys reacted with monoclonal antibody recognizing the EIIIA region of cellular FN. A, C, E, and G represent the outer stripe of the outer medulla; B, D, F, and H represent the inner stripe of the outer medulla. The 3-h time point is demonstrated in A-B, the 24-h time point in C-F, and the 120-h time point in G-H. In the contralateral kidney (A-D), FN containing EIIIA is detected in the outer and inner stripe outlining tubular basement membranes. Interstitial staining does not increase at 24 h (C-D) nor is EIIIA-FN detected in tubular lumens (C-D). In sham-operated kidneys (E-H), FN containing EIIIA is absent in the outer stripe (E, G) and is barely detected in the inner stripe (arrows, F, H). Bar = 28 µm.

To confirm biochemically our immunocytochemical observations, tissue extracts were prepared for immunoblotting from normal, 0-, 1-, 3-, 24-, 48-, and 120-h postischemic as well as contralateral control or mock-operated kidneys. Western blots showed that FN containing the EIIIA segment increases in response to ischemic injury. Levels of EIIIA-FN significantly rise at 24 h in ischemic kidneys (Fig. 7A) and remain elevated at 48 and 120 h (Fig. 7A) compared with contralateral (Fig. 7B) and mock (Fig. 7C) kidneys at corresponding time points. In contrast to the immunostaining data, however, significant levels of EIIIA-FN at 3 h postischemia (Fig. 7A) or in contralateral kidneys (Fig. 7B) are not always detected. This may be due to low levels of expression localized to only a limited region of the kidney that is below the limit of detectability when the entire kidney is taken for Western blot analysis. The appearance of EIIIA-FN at low levels in mock kidneys at each time point may represent normal expression in the papillary region detected by immunostaining (data not shown). Such immunostaining is also present in contralateral kidneys (data not shown).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 7.   Immunoblot of kidney tissue (25 µg/lane) after 6% SDS-PAGE probed with mouse anti-human EDA FN and donkey anti-mouse HRP; HRP was visualized with diaminobenzidine. In this series of postischemic kidneys (A), FN containing EIIIA (220 kDa under reducing conditions) is detected at significant levels after 24 h of injury and continues to increase thereafter. In contralateral control (B) or mock-operated (C) kidneys, EIIIA-FN is barely detected. Ischemic kidney tissue (120 h) served as positive control (+C).

EIIIB-FN. FN containing the EIIIB region was examined next. EIIIB, like EIIIA, is unique to cellular FN. EIIIB-FN was not detected in kidney sections at any of the time points examined after ischemic injury. It is also not detected in normal adult rat (42, 44), mouse (46), or human (34) kidneys. As a positive control for immunostaining, EIIIB-FN was detected in Descemet's membrane of the adult rat cornea (data not shown; 46).

V95-FN. Localization of the V95 region of FN, which in the rat is found in a fraction of both plasma and cellular FNs (54, 55), was also examined. At 0 h postischemia, little if any FN containing the V95 region is detected in the outer (arrows, Fig. 8A) and inner stripes (Fig. 8B). One to three hours later, localization in the outer stripe (Fig. 8C) does not change; however, in the inner stripe (Fig. 8D), FN containing V95 begins to localize to some lumenal compartments (asterisks, Fig. 8D).


View larger version (130K):
[in this window]
[in a new window]
 
Fig. 8.   Immunofluorescent staining of cryostat sections of postischemic kidneys reacted with polyclonal antibody recognizing the V95 region of rat plasma and cellular FN. A, C, E, and G represent the outer stripe of the outer medulla whereas B, D, F, and H represent the inner stripe of the outer medulla. At 0 h reperfusion (A-B), FN containing the V95 region is not detected in the outer medullary region except for infrequent patchy distribution that faintly associates with renal tubules (arrow, A). It is rarely detected in the interstitium 3 h after reperfusion (arrow, C) when it begins to localize to the luminal space of some thick limbs in the inner stripe (asterisks, D). At 24 h after reperfusion (E-F), staining intensity for FN containing V95 increases in the interstitium around S3 proximal tubules (E); in the inner stripe a delicate fibrillar staining is seen between tubules (F). Localization of the V95 isoform to lumens of thick ascending limbs also increases at this time (asterisks, F). At 120 h after reperfusion (G-H), FN containing V95 continues to increase in the interstitial compartment of the outer medulla, associating with basement membranes of renal tubules; V95-FN is absent from the luminal space in the inner stripe. Bar = 40 µm.

At 24-48 h after reperfusion, the interstitial matrix between renal tubules of the outer stripe (Fig. 8E) is strongly highlighted whereas, in the inner stripe (Fig. 8F), delicate staining predominates in the interstitial space. V95-FN is also detected more frequently at high levels in luminal compartments (asterisks, Fig. 8F). At 120 h postischemia, immunostaining becomes intense in an expanded interstitium in both the outer (Fig. 8G) and inner (Fig. 8H) stripes but is no longer detected in tubular lumens (inner stripe, Fig. 8H).

In contralateral and mock kidneys at 0 and 1-3 h, localization of V95-FN is comparable to that observed in corresponding postischemic animals (see Fig. 8, A-D); i.e., little if any is detected in the outer medulla (data not shown). Contrary to the postischemic animal at 3 h, however, FN containing V95 is not found in the luminal space (data not shown). At 24, 48, and 120 h in contralateral kidneys, some interstitial staining of V95 FN begins to be observed; however, immunostaining is not extensive because the interstitium is not enlarged (data not shown) as in ischemic animals at these times. In addition, V95-FN is not detected in the luminal space (data not shown). Mock animals at 24, 48, and 120 h show infrequent, faint staining of the interstitium (data not shown), similar to that observed at 0 and 1-3 h postischemia (see Fig. 8, A-D); luminal staining, however, is not observed at any time point (data not shown).

Thus in response to ischemia-reperfusion, FN containing the EIIIA but not the EIIIB region increases dramatically in the outer and inner stripes of the injured kidney and continues to be produced at high levels 120 h later. FN containing V95 also increases, albeit more slowly and at lower levels than EIIIA; it also persists at 120 h. Both EIIIA and V95-FNs localize to the interstitium and surround tubular basement membranes. V95-, but not EIIIA- or EIIIB-containing FN, is found in tubular lumens of the distal nephron as early as 3 h after reperfusion in the injured kidney, disappearing by 120 h postischemia.

Distribution and Expression of FN Isoforms in the Cortex

FN isoforms were also immunolocalized in the cortex after ischemic injury to determine whether either expression or distribution in this region was affected, as in the outer and inner stripes. We also examined whether the immunostaining pattern provided evidence of glomerular damage, which could explain the source of luminal FN in both this and our previous study (76). Glomerular injury would disrupt the glomerular filtration barrier, allowing access of plasma proteins (greater than 70 kDa) such as FN into Bowman's space.

Total FN. At 0 (Fig. 9A), 1, 3 (Fig. 9B), 24, 48 (Fig. 9C), and 120 h (Fig. 9D) postischemia, anti-total FN antibody highlights Bowman's capsule and the glomerular capillary tuft. Total FN is not observed in the urinary space of renal corpuscles at any time (asterisk, Figs. 9, A-D); however, from 3 to 48 h after reperfusion, it is more frequently detected in tubular lumens of the distal nephron adjacent to glomeruli (double asterisk, Figs. 9, B and C, respectively). The latter observation of FN in tubular lumens of nephron segments distal to glomeruli is consistent with results from the outer (see Fig. 2E) and inner stripes (see Fig. 2, D and F).


View larger version (157K):
[in this window]
[in a new window]
 
Fig. 9.   Immunofluorescent staining of cryostat sections of postischemic cortex reacted with anti-total FN polyclonal antibody. At 0 (A), 3 (B), 48 (C), and 120 h (D) postischemia, total FN outlines Bowman's capsule, the glomerular capillary tuft and proximal and distal tubules in the cortex; it also localizes to the interstitium, significantly increasing in this location at 48 (C) and 120 h (D) after reperfusion. Total FN is absent from the urinary space (*) surrounded by Bowman's capsule at all time points even though at 3 (B) and 48 h (C) postischemia it concentrates in lumens of nephron segments distal to glomeruli (**). Bar = 29 µm.

At all time points after ischemic reperfusion injury (Figs. 9, A-D), total FN outlines basement membranes of proximal and distal tubules in the cortex. Between 24 and 48 h after injury, it also strongly localizes to the renal interstitium (Fig. 9C). At 120 h postischemia, as seen in the outer and inner stripes (see Figs. 2, G and H, respectively), immunostaining of an expanded interstitium remains intense and total FN is no longer detected in the lumenal space (Fig. 9D).

Similar localization of total FN outlining glomeruli and proximal and distal tubules is observed in contralateral (see Fig. 10, A and B representing the 24 and 120 h time points, respectively; data not shown for 0 and 3 h) and mock kidneys (see Fig. 10, E and F representing the 24 and 120 h time points, respectively; data not shown for 0 and 3 h). Contrary to the postischemic kidney (for 3 and 48 h, see Fig. 9, B and C, respectively), however, lumenal staining is not present in the distal nephron adjacent to glomeruli at any time (for contralateral and mock representing the 24 h time point, see Fig. 10, A and E, respectively). Interstitial staining also does not increase (for contralateral and mock representing the 24 and 120 h timepoint, see Fig. 10, A-B and E-F, respectively), contrary to that observed in the postischemic kidney where the interstitium expands (compare to Fig. 2, E-H for 24 and 120 h, respectively; Fig. 9D, 120 h).


View larger version (116K):
[in this window]
[in a new window]
 
Fig. 10.   Immunofluorescent staining of cryostat sections of the cortex from contralateral (A-D) and mock-operated (E-H) kidneys at 24 h (A, C, E, and G) and 120 h (B, D, F, and H), reacted with either polyclonal antibody recognizing total FN (A, B, E, and F) or monoclonal antibody recognizing the EIIIA region of cellular FN (C, D, G, and H). In the cortex of contralateral (A-B) and mock (E-F) kidneys, total FN outlines Bowman's capsule, the glomerular capillary tuft, and proximal and distal tubules; it also localizes to the interstitium. Total FN is absent, however, from the urinary space surrounded by Bowman's capsule (A, B, E, and F) and from tubular lumens of distal nephron segments (A, B, E, and F). Interstitial staining does not increase at 120 h (B, F). FN containing the EIIIA region highlights glomerular elements in contralateral (C-D) and mock kidneys (arrows, G-H), although to a lesser extent in the latter. The dashed lines in G-H demarcate Bowman's capsule. Renal tubules stain nonspecifically in G. Bar = 28 µm.

EIIIA-FN. Immunostaining of both glomeruli and the interstitium of the cortex was examined with antibody recognizing the EIIIA region of FN. In glomerular regions at 0 h postischemia, anti-EIIIA antibody faintly demarcates the connective tissue of the capillary tuft (Fig. 11A; 34). This staining pattern does not change 1-3 h after reperfusion (data not shown). However, 24-48 h after injury (Fig. 11B), components of the renal corpuscle, including Bowman's capsule, stain more intensely, persisting at 120 h postischemia (Fig. 11C). FN containing EIIIA does not localize to Bowman's space at any time after reperfusion (asterisk, Figs. 11, A-C) and is absent from tubular lumens of the distal nephron.


View larger version (176K):
[in this window]
[in a new window]
 
Fig. 11.   Immunofluorescent staining of cryostat sections of postischemic cortex at 0 (A and D), 48 (B and E), and 120 h (C and F) after reperfusion reacted with monoclonal antibody recognizing the EIIIA region of cellular FN (A-C) or polyclonal antibody against the V95 region (D-F). At 0 h after reperfusion (A, D), EIIIA (A)-, and V95 (D)-FNs faintly localize to glomerular connective tissue; no reactivity is seen in the renal interstitium. At 48 h after reperfusion (B and E), the renal corpuscle is highlighted with both anti-EIIIA (B) and anti-V95 (E) antibodies; Bowman's capsule and the capillary tuft are outlined, although the localization for V95-FN appears to be less distinct. Some tubular basement membranes are also immunoreactive with both antibodies. In particular, EIIIA-FN shows a gradient of staining with greater intensity of localization in regions proximal to the outer medulla (B); cortical areas distal to this site are more weakly stained (B). A gradient of staining is not detected to the same extent for V95-FN (E). At 120 h postischemia (C, F), immunostaining of the renal corpuscle and an expanded interstitium remains intense for EIIIA-FN (C); however, a gradient of staining (C) is not as prevalent as at 48 h. In addition, V95-FN (F) is not present to the same extent as EIIIA-FN at 120 h postischemia. Note that at none of the timepoints after reperfusion is EIIIA (A, B, C)- or V95 (D, E, F)-FNs found in Bowman's space (*). Bar = 29 µm.

FN containing the EIIIA region was also localized in the cortical interstitium. At 0 h postischemia (Fig. 11A), EIIIA-FN does not associate with tubular basement membranes or the interstitial matrix, in agreement with the immunostaining data in the outer medulla at this time (see Figs. 5, A and B). Interestingly, no increase at 3 h postischemia is observed (data not shown), in contrast to the rise of EIIIA-FN in the outer and inner stripes (see Fig. 5, C and D). At 24-48 h after injury, distribution of EIIIA-FN in the cortical interstitium is unusual and does not recapitulate earlier patterns observed with this antibody. Indeed, a gradient of staining is frequently detected with greater intensity of localization in cortical areas near the outer medullary region (Fig. 11B) where injured S3 proximal tubules reside. Localization is confined to an expanded interstitium, including areas juxtaposed to basement membranes. The interstitial matrix in cortical areas distant from the outer medulla shows weaker localization (Fig. 11B) or does not stain at all (data not shown). At 120 h postischemia, immunostaining of an expanded interstitium remains intense (Fig. 11C). A gradient of staining continues to be present to some extent, with greater intensity in regions adjacent to the outer medullary region, diminishing in regions distant from it.

In contralateral kidneys at all time points, FN containing EIIIA identifies the connective tissue elements of the glomerulus and does not appear to localize to the interstitium surrounding proximal and distal tubules (Fig. 10, C and D, representing the 24 and 120 h time points, respectively; data not shown for 0 and 1-3 h). Faint immunostaining of glomerular connective tissue is observed in mock kidneys at all time points (arrows, Fig. 10, G and H, representing the 24 and 120 h time points, respectively; data not shown for 0 and 1-3 h). Again, none is detected in the interstitium.

EIIIB-FN. The FN isoform containing the EIIIB region was not detected in the cortex either before (42) or after ischemic injury (data not shown).

V95-FN. Distribution and expression of FN containing the V95 region was examined in the glomerular and interstitial regions of the cortex. In the glomerular region at 0 (Fig. 11D), 3 (data not shown), 48 (Fig. 11E), and 120 h (Fig. 11F) postischemia, V95-FN weakly localizes to the connective tissue surrounding the capillary tuft and steadily increases in Bowman's capsule. FN containing V95 is absent from the urinary space at all times after reperfusion (asterisk, Fig. 11, D-F) but is sometimes seen in the lumen of the distal nephron between 3 and 48 h after reperfusion (data not shown).

V95-FN also localizes to the cortical interstitium. From 0 (Fig. 11D) to 3 h (data not shown) postischemia, immunostaining with the anti-V95-FN antibody is rarely detected, consistent with our observation in the outer and inner stripes at this time (see Fig. 8, A-D). However, at 24-48 h postischemia, V95-FN increases in the interstitial compartment surrounding tubular basement membranes (Fig. 11E). A gradient of staining, ranging from greater intensity in cortical areas adjacent to the outer medulla to lesser intensity in cortical regions distant from it, is not readily detected, in contrast to the immunstaining pattern observed for EIIIA-FN (see Fig. 11B). At 120 h postischemia, V95-FN is not present to the same extent as EIIIA (see Fig. 11C) or total FN (see Fig. 9D). Antibody recognizing V95 strongly outlines only some tubules in this location (Fig. 11F).

In contralateral kidneys at all time points, FN containing V95 weakly localizes to the connective tissue of the capillary tuft and to Bowman's capsule (data not shown), as in the postischemic injured kidney at 0 h (see Fig. 11D). None is detected in the luminal space at any time (data not shown). Faint, patchy immunostaining is infrequently seen in the interstitial compartment (data not shown). A similar pattern is observed in cortical regions of mock kidneys at all time points, except that interstitial staining is barely detectable (data not shown).

Thus in the cortex after ischemic injury, no FN isoforms are detected in the urinary space of the glomerulus. In addition, the FN isoform containing EIIIA and, to a lesser extent, V95-FN develops a gradient of expression, with more localizing in cortical regions near the outer medulla and less in regions distant from it. Both isoforms localize to the interstitium surrounding tubular basement membranes. FN containing EIIIB is not detected.

Plasma But Not Cellular FN is Voided in the Urine

Immunostaining with anti-total FN and anti-V95 antibodies indicated that FN localized to tubular lumens shortly after reperfusion (1-3 h) peaked when injury predominated (24-48 h) and later disappeared as regeneration continued (120 h reperfusion; see Figs. 2 and 8, respectively; 76). Loss of FN from tubular lumens could be due to excretion. To confirm this, urine collected at 24-h intervals from animals that had undergone unilateral renal ischemia was analyzed for the presence of plasma and/or cellular FN. Urine from mock-operated animals served as control. Urine containing equal amounts of protein were electrophoresed, and SDS gels were immunoblotted with either anti-total or anti-cellular FN antibody recognizing human EDA.

Immunoblotting with the anti-total FN antibody demonstrates that FN is voided in the urine in response to ischemia-reperfusion injury. Two patterns emerge. In some animals (n = 3), total FN is voided at increasing levels (Fig. 12A), beginning as early as 24 h after reperfusion, peaking 72-96 h after reperfusion and in some instances declining thereafter. In other animals (n = 4), a biphasic excretion pattern is seen (Fig. 12A). Total FN is voided at high levels 24 h after reperfusion, declines 48-72 h after reperfusion, and again increases from 72-120 h, reaching levels equivalent to that at the 24-h time point. In urine of mock operated or normal animals, total FN is excreted at very low levels (Fig. 12A).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 12.   Immunoblots of urine representing equal amounts of protein resolved by 6% SDS-PAGE, reacted with chemiluminescence reagents. A and B: 5 and 10 µg protein/lane, respectively. Urine was collected at 24-h intervals from animals that had undergone unilateral renal ischemia or from mock-operated animals; animals were housed in metabolic cages. Each immunoblot is from 1 representative animal. In the postischemic animal, antibody recognizing total FN (A) shows that FN is excreted in the urine in 2 patterns. In the first, it is voided at increasing levels from 24-120 h after reperfusion with high levels predominating between 72-120 h. In the second, a biphasic pattern is observed. High levels of FN are initially excreted at 24 h after reperfusion, followed by a precipitous decrease and subsequent increase that persists at 120 h. In the mock animal, fibronectin is excreted at very low levels, comparable to that detected in the urine of normal animals. Note the lower molecular weight breakdown fragments of FN excreted in the urine. Purified plasma FN (2.5 ng) is used as the positive control (+C) in A. Antibody recognizing the EDA region of human cellular FN (B) shows that cellular FN containing EIIIA is not excreted in the urine in either the ischemic or mock animal. Ischemic kidney tissue (5 µg, 48 h postischemic) is used as positive control (+C) in B.

In contrast to the data with the anti-total FN antibody, immunoblotting with anti-cellular EDA antibody confirms that cellular FN synthesized by renal epithelia or connective tissue cells is not detected in the urine at any time after ischemia-reperfusion (Fig. 12B). It is also not detected in urine collected from mock-operated animals (Fig. 12B). Thus cellular FN is not excreted, suggesting that all the FN that is excreted is from the plasma and that it is plasma not cellular FN that is found in tubular lumens.

Distribution and Expression of FN Isoforms 6 Wk After Ischemic Injury

The observation that total FN-, EIIIA-, and V95-containing FN isoforms persist at high levels 120 h after reperfusion when repair from ischemic injury is almost complete and redifferentiation of the damaged tubular epithelium predominates (1, 72, 76) raised the question of whether the distribution and expression of FN isoforms containing EIIIA and/or V95 persists at later times.

At 6 wk postischemia, FN continues to localize at high levels in previously injured regions of the outer medulla, identified by the heterogeneous shapes and sizes of the regenerated tubules. Antibody against total FN strongly stains the interstitial compartment, sometimes concentrating at higher levels adjacent to basement membranes of renal tubules (Fig. 13A). In contrast, antibodies to EIIIA and V95-FNs mainly identify tubular basement membranes of varying thicknesses, whereas other basement membranes are not outlined (Fig. 13, B-C, respectively). The interstitial compartment contains some EIIIA and V95-FN, however, at significantly lower levels than that observed for total FN.


View larger version (90K):
[in this window]
[in a new window]
 
Fig. 13.   Immunofluorescent staining of cryostat sections of 6-wk postischemic kidney reacted with polyclonal and monoclonal antibodies to FN. Total FN (A) strongly localizes to the interstitial space of the outer medulla and concentrates at high levels in the connective tissue adjacent to some renal tubules. FN containing the EIIIA (B) or V95 (C) regions primarily identifies tubular basement membranes of varying thicknesses in this region; overall, EIIIA and V95-FNs are less conspicuous in the interstitium than total FN. Bar = 23 µm.

In the cortex, FN containing the EIIIA or V95 regions is not detected in association with basement membranes or the interstitium (data not shown); sclerosis of glomeruli also is not evident (data not shown).

FN containing EIIIB is not detected in either the outer medulla or cortex of the 6-wk postischemic kidney (data not shown).

Thus EIIIA and V95-FNs are found in the 6-wk postischemic kidney, localizing to the basement membrane region of previously injured tubules. They are also found to a lesser extent in the surrounding interstitium.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We demonstrate using an in vivo model of unilateral renal ischemia that production of FN splice variants dramatically changes as a result of renal injury and repair (Table 1). In ischemic kidneys that are not reperfused (0 h), the alternatively spliced forms of FN, which contain the EIIIA, EIIIB, and/or V95 regions, are absent from the renal interstitium. However, at early times after reperfusion (1-3 h), FN containing EIIIA increases in this location in the outer medulla whereas FN containing V95 does not. The isoform containing V95, but not the EIIIA or EIIIB region, is found in a few lumens of the distal nephron. At 24-48 h postischemia, as further injury and regeneration coordinately occur, localization of both EIIIA- and V95-containing FN isoforms increases in the interstitial matrix in both the outer medulla and cortex, with the increase in EIIIA-FN being more dramatic. The V95-containing FN isoform, but not that containing EIIIA, also frequently fills the luminal space. As regeneration continues at 120 h after reperfusion, EIIIA- and V95-containing FN strongly localize to the interstitial compartment, and V95-FN is no longer detected in tubular lumens. Luminal FN is ultimately excreted in the urine. Six weeks after ischemic injury, FN containing EIIIA and/or V95 persists around some renal tubules.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Summary of the distribution of the alternatively spliced segments of fibronectin in the postischemic rat kidney

Our data using polyclonal and monoclonal antibodies specific for unique regions of the various isoforms of FN indicate that luminal FN originates from plasma. FN in tubular spaces was detected by immunohistochemistry with antibodies recognizing both total and V95-FNs but not with antibodies against the EIIIA- or EIIIB-containing cellular isoforms. In addition, FN excreted in the urine was not detected by antibody specific for cellular FN.

It is unclear how plasma FN enters the luminal space. There is no evidence that it is made by other cell types in addition to hepatocytes (61). Furthermore, our data suggest that luminal plasma FN does not originate from damage to the glomerular filtration barrier, which normally is impermeant to plasma proteins. Total or V95-FNs, with molecular weights of ~440 kDa, were not detected in Bowman's space at any time after ischemia. We believe it likely, therefore, that plasma proteins, including FN, extravasate from interstitial blood vessels into the interstitial space from where it penetrates damaged tubules and enters the lumen. Permeability changes in interstitial blood vessels would allow the escape of plasma FN into the interstitium. In combination with tubulorrhexis and/or disruption to the epithelial permeability barrier (59, 69), plasma FN would then gain entry into tubular lumens. Once in the lumen of the injured tubule, plasma FN concentrates in more distal nephron segments.

Under these circumstances, luminal plasma FN might play a very significant role in the pathophysiology of acute renal failure. Our data indicate that within the first 48 h of ischemic injury, FN is detected by immunohistochemistry in the luminal space of the injured kidney while simultaneously being excreted in the urine. Although we have no evidence plasma FN is occluding the lumen, the high concentration of plasma FN in this location may suggest that its movement is retarded. This may occur through the formation of obstructive complexes with other molecules such as the Heymann antigen gp330 (39) on microvilli shed in response to injury (16, 65) as well as other cellular debris, contributing to the formation of casts. We do not believe plasma FN adheres to sloughed dead or viable cells in the luminal space, because FN fibrils, which assemble on cell-FN interactions (27, 71, 73-74), are not detected. Ultimately, all plasma FN is excreted, indicating that any obstruction is not permanent (see Figs. 2H and 8H).

We also demonstrate that after ischemic injury the FN isoforms containing the EIIIA and V95 regions but not EIIIB localize to the renal interstitium surrounding tubular basement membranes. Before injury, FN containing EIIIA or V95 is not detected in this location. Within 3 h of reperfusion, however, an increase in EIIIA but not V95-FN is observed in the interstitial matrix of the outer medulla and continues to increase at 24-48 h after injury. Although V95-FN increases somewhat at this time, a parallel rise is not detected. Both persist at high levels in the renal interstitium 120 h after reperfusion.

The upregulation of FN isoforms suggests that ischemic injury may stimulate a signal regulating the production of the alternatively spliced forms. Transforming growth factor-beta (TGF-beta ), a multifunctional cytokine that operates in either a paracrine or autocrine manner, stimulates fibronectin synthesis (30) and regulates production of the EIIIA-FN isoform by acting on FN pre-mRNA (13, 35). It is derived from a number of cell types including platelets (5), wound macrophages (49), and fibroblasts/myofibroblasts (75), as well as injured proximal tubular epithelial cells (10). It has a known role in the pathogenesis of renal disease (11, 58) and is believed to promote tissue regeneration after renal injury (8, 10). It is unclear which cells at the various time points after reperfusion produce TGF-beta in the in vivo model of unilateral renal ischemia used in this study. Whether TGF-beta acts in a paracrine or autocrine fashion on injured epithelial or connective tissue cells (e.g., infiltrating macrophages, fibroblasts/myofibroblasts) to promote the synthesis, secretion, and deposition into the extracellular matrix of FN containing the EIIIA region also needs to be determined. TGF-beta when administered in vitro increases expression of EIIIA-FN mRNA by proximal tubule cells (35, 66); its immunoneutralization in vivo in a bilateral model of renal injury also attenuates the rise in FN containing EIIIA (9). The production of TGF-beta and other paracrine growth factors may explain the unusual gradient of staining for EIIIA-FN in the cortex, which is intense in regions adjacent to the outer medulla (see Fig. 11B). Paracrine growth factors may also be responsible for the observation that EIIIA-FN is not detected in the cortex until 24 h after reperfusion (Fig. 11B) even though in the outer and inner stripes it is present at high levels soon after reperfusion (1-3 h postischemia; see Fig. 5, C-D).

Growth factors produced by the injured kidney may also explain the appearance of the alternatively spliced forms in the contralateral kidney detected by immunostaining. The FN isoform containing EIIIA was detected within hours in the contralateral kidney, whereas the FN isoform containing V95 was detected later. Both persisted at the latest time point we examined, although levels did not increase from that seen initially and overall were less than that seen in the ischemic kidney. Perhaps growth factors, such as TGF-beta 1, released by the injured ischemic kidney enter the systemic circulation; in this location, it may act on the contralateral kidney to stimulate the production and accumulation of FN containing EIIIA and/or V95. Alternatively, the experimental procedure of unilaterally clamping the renal artery and vein may have resulted in some generalized reduction in blood pressure, resulting in reduced perfusion of the contralateral kidney.

In the postischemic kidney, the role of FN containing EIIIA is unknown; however, our data indicate that it may be necessary for regeneration. EIIIA-FN is widely expressed during organogenesis and tissue remodelling in the embryo (20-21, 43-44, 47, 64) and during wound healing of various tissue types (2-3, 7, 14, 17, 20, 25, 28, 41-42, 60, 67). In each of these cases, FN containing EIIIA may be required for cell migration, proliferation, and differentiation. The association of EIIIA-FN with tubular basement membranes may promote migration of remaining epithelial cells after damaged cells have exfoliated, as well as the spreading of adherent epithelia to fill in denuded areas of basement membrane. Similarly, it may stimulate epithelial proliferation, which occurs during this time and is necessary for repopulation of the damaged tubule (72). These cellular responses are key elements of epithelial redifferentiation after renal ischemic injury (62, 76). It would be interesting to examine at the ultrastructural level whether EIIIA-FN is indeed an integral component of regenerating basement membranes and whether in this location it mediates these cell-extracellular matrix interactions, perhaps by inducing the expression of novel extracellular matrix receptors, such as the alpha 5beta 1 integrin, the major fibronectin receptor, and/or contributing to the altered distribution of other integrins (76).

FN containing EIIIA may also play a role in the fibrotic response after renal ischemic injury. In this regard, FN is believed to be the first extracellular matrix molecule deposited in renal interstitial fibrosis (18). In the liver, FN containing EIIIA activates the conversion of normal hepatic lipocytes into myofibroblast-like cells, a critical event in the initiation of fibrogenesis in the liver (31). In the formation of granulation tissue in wounded skin, EDA FN is necessary for induction of the myofibroblastic phenotype by TGF-beta 1 (57). Whether deposition of FN containing EIIIA in the postischemic kidney is necessary for the conversion of stromal fibroblasts and/or perivascular cells into myofibroblast-like cells (18) is unknown. However, TGF-beta mediates this activation (15) and also stimulates production of FN containing EIIIA (6). We see that in the injured kidney FN containing EIIIA is expressed soon after reperfusion, continues to increase in an expanded interstitium, and persists weeks later in association with thickened basement membranes. Perhaps deposition of EIIIA-FN is the key extracellular matrix component that initiates renal fibrosis after ischemic injury.

More is known about the role of FN containing the V95 region, which in the rat is a component of both plasma and cellular FNs. FN exists as a dimeric glycoprotein, and the V95 region must be present in at least one subunit for its secretion to take place (for review, see Refs. 51-52). Our immunostaining data clearly show that although the EIIIA isoform is present in high amounts in the renal interstitium after ischemic injury, levels of V95 are not necessarily comparable. Similar results have been obtained by immunohistochemistry in skeletal and heart muscle, lung parenchyma, small intestine, pancreas, and peripheral nerve (46). This apparent discrepancy could arise from the presence of the V95 region in only one subunit of the FN dimer and/or from differences in antibody sensitivity or epitope masking.

These same reasons could explain why the FN isoform containing the V95 region is not detected in tubular lumens at the same frequency as total FN, which recognizes both the plasma and cellular forms. The V95 region in the rat is one of three variants produced by alternative splicing of the V region exon (for review, see Refs. 19, 51-52). These variants include V120, which contains all V120 region amino acids, V95, which lacks the first 25 amino acids, and V0, which lacks the entire V region. In rat plasma FN, ~50% of the FN subunits are V0 and 50% are a combination of V120 and V95 (54). Considering that less than 50% of the FN subunits circulating in plasma are V95, it is not surprising that the frequency of the V95 isoform in tubular lumens is not equivalent to that observed with the total FN antibody.

At 6 wk postischemic injury, FN isoforms containing EIIIA and V95 strongly localize to thickened basement membranes of some tubules that initially were damaged and appear incompletely regenerated; localization to the surrounding interstitium is weak. Staining with anti-total FN antibody indicates that total FN is found in tubular basement membranes and is strongly expressed in the interstitial compartment. The data suggest incomplete recovery of some regions of the postischemic kidney. In addition, plasma FN, possibly escaping from interstitial blood vessels, appears to be trapped in the connective tissue compartment, having been deposited into the extracellular matrix. It is possible that plasma FN is prevented from entering the luminal space either because the thickened basement membranes, containing EIIIA and V95 FNs, inhibit its passage and/or the epithelial permeability barrier is reestablished.

Our observation of incomplete recovery 6 wk after unilateral ischemic injury may be clinically relevant. In the patient population, the postischemic kidney has a tremendous capacity to completely regenerate, restoring normal renal function. However, it is possible that some nephrons do not completely recover. We believe that our observation in the unilateral model showing incomplete repair of some nephron segments could indicate heterogeneity of nephron function postischemia (4, 23). Long-term effects could result in chronic renal failure, glomerulosclerosis, and tubulo-interstitial damage (63). Similar processes may ultimately occur in patients suffering from ischemic injury.

In conclusion, we show that in response to ischemic injury, the FN isoforms containing the EIIIA and V95 regions that are not normally expressed in the renal interstitium are significantly upregulated, suggesting a possible dual role in regeneration of the damaged kidney and in fibrosis. Tubular FN originates from plasma and may contribute to obstruction. Determining the role of extracellular matrix molecules in renal ischemic injury and repair and how they interact with damaged and regenerating cells may facilitate our understanding of the pathogenesis of acute renal failure. Knowledge of these processes may contribute to the identification of novel therapeutics aimed at limiting injury or speeding recovery.


    ACKNOWLEDGEMENTS

We thank I. Virtanen and R.O. Hynes for antibodies, the Morphology Core of the Harvard Digestive Disease Center (DK-34854) for use of the Leica cryostat, and Dr. Elizabeth D. Hay for use of the Zeiss Axiophot microscope.


    FOOTNOTES

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants RO1-DK-46768 (to K.S. Matlin) and R37-DK-39773 (to J. V. Bonventre).

Address for reprint requests and other correspondence: A. Zuk, Dept. of Surgery, Beth Israel Deaconess Medical Center, Bldg. DA-880, 330 Brookline Ave., Boston, MA 02215 (E-mail: azuk{at}caregroup.harvard.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10 February 2000; accepted in final form 9 February 2001.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Abbate, M, Brown D, and Bonventre JV. Expression of NCAM recapitulates tubulogenic development in kidneys recovering from acute ischemia. Am J Physiol Renal Physiol 277: F454-F463, 1999[Abstract/Free Full Text].

2.   Alonso, J, Gomez-Chiarri M, Ortiz A, Seron D, Condom E, Lopez-Armada MJ, Largo R, Barat A, and Egido J. Glomerular up-regulation of EIIIA and V120 fibronectin isoforms in proliferative immune complex nephritis. Kidney Int 50: 908-919, 1996[ISI][Medline].

3.   Alonso, J, Mampaso F, Martin A, Palacios I, and Egido J. Changes in the pattern of fibronectin mRNA alternative splicing in acute experimental mesangioproliferative nephritis. Lab Invest 79: 185-194, 1999[ISI][Medline].

4.   Arendshorst, WJ, Finn WF, and Gottschalk CW. Micropuncture study of acute renal failure following temporary renal ischemia in the rat. Kidney Int Suppl 6: S100-S105, 1976[Medline].

5.   Assoian, RK, Komoriya A, Meyers A, Miller DM, and Sporn MB. Transforming growth factor beta  in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 258: 7155-7160, 1983[Abstract/Free Full Text].

6.   Balza, E, Borsi L, Allemanni G, and Zardi L. Transforming growth factor beta  regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett 228: 42-44, 1988[ISI][Medline].

7.   Barnes, JL, Torres ES, Mitchell RJ, and Peters JH. Expression of alternatively spliced fibronectin variants during remodeling in proliferative glomerulonephritis. Am J Pathol 147: 1361-1371, 1995[Abstract].

8.   Basile, DP. The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Curr Opin Nephrol Hypertens 8: 21-30, 1999[ISI][Medline].

9.   Basile, DP, Martin DR, and Hammerman MR. Extracellular matrix-related genes in kidney after ischemic injury: potential role for TGF-beta in repair. Am J Physiol Renal Physiol 275: F894-F903, 1998[Abstract/Free Full Text].

10.   Basile, DP, Rovak JM, Martin DR, and Hammerman MR. Increased transforming growth factor-beta 1 expression in regenerating rat renal tubules following ischemic injury. Am J Physiol Renal Fluid Electrolyte Physiol 270: F500-F509, 1996[Abstract/Free Full Text].

11.   Border, WA, and Noble NA. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 51: 1388-1396, 1997[ISI][Medline].

12.   Borsi, L, Carnemolla B, Castellani P, Rosellini C, Vecchio D, Allemanni G, Chang SE, Taylor-Papadimitriou J, Pande H, and Zardi L. Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol 104: 595-600, 1987[Abstract].

13.   Borsi, L, Castellani P, Risso AM, Leprini A, and Zardi L. Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 261: 175-178, 1990[ISI][Medline].

14.   Brown, LF, Dubin D, Lavigne L, Logan B, Dvorak HF, and Van De Water L. Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am J Pathol 142: 793-800, 1993[Abstract].

15.   Desmouliere, A, Geinoz A, Gabbiani F, and Gabbiani G. Transforming growth factor-beta 1 induces alpha -smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122: 103-111, 1993[Abstract].

16.   Donohoe, JF, Venkatachalam MA, Bernard DB, and Levinsky NG. Tubular leakage and obstruction after renal ischemia: structural-functional correlations. Kidney Int 13: 208-222, 1978[ISI][Medline].

17.   Dubin, D, Peters JH, Brown LF, Logan B, Kent KC, Berse B, Berven S, Cercek B, Sharif BF, Pratt RE, Dzau VJ, and Van De Water L. Balloon catheterization induces arterial expression of embryonic fibronectins. Arterioscler Thromb Vasc Biol 15: 1958-1967, 1995[Abstract/Free Full Text].

18.   Eddy, AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7: 2495-2508, 1996[Abstract].

19.   ffrench-Constant, C. Alternative splicing of fibronectin-many different proteins but few different functions. Exp Cell Res 221: 261-271, 1995[ISI][Medline].

20.   ffrench-Constant, C, and Hynes RO. Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. Development 106: 375-388, 1989[Abstract].

21.   ffrench-Constant, C, and Hynes RO. Patterns of fibronectin gene expression and splicing during cell migration in chicken embryos. Development 104: 369-382, 1988[Abstract].

22.   ffrench-Constant, C, Van de Water L, Dvorak HF, and Hynes RO. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol 109: 903-914, 1989[Abstract].

23.   Finn, WF. Nephron heterogeneity in polyuric acute renal failure. J Lab Clin Med 98: 21-29, 1981[ISI][Medline].

24.   Glaumann, G, Glaumann H, and Trump BF. Studies of cell recovery from injury. III Ultrastructural studies of the recovery of the pars recta of the proximal tubule (P3) segment of the rat kidney from temporary ischemia. Virchows Arch 25: 281-308, 1977.

25.   Glukhova, MA, Frid MG, Shekhonin BV, Vasilevskaya TD, Grunwald J, Saginati M, and Koteliansky VE. Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 109: 357-366, 1989[Abstract].

26.   Goligorsky, MS. Acute renal failure: New concepts and therapeutic strategies. In: Contemporary Issues in Nephrology, edited by Stein JH.. New York: Churchill Livingstone, 1995, p. 499.

27.   Hayman, EG, and Ruoslahti E. Distribution of fetal bovine serum fibronectin and endogenous rat cell fibronectin in extracellular matrix. J Cell Biol 83: 255-259, 1979[Abstract].

28.   Hosoi, M, Takasaki I, Pavlova-Rezakova A, Himeno H, Chobanian AV, and Brecher P. Selective induction of an embryonic fibronectin isoform in the rat aorta in vitro. Circ Res 73: 689-695, 1993[Abstract].

29.   Hynes, RO. Fibronectins, edited by Rich A.. New York: Springer-Verlag, 1990.

30.   Ignotz, RA, and Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261: 4337-4345, 1986[Abstract/Free Full Text].

31.   Jarnagin, WR, Rockey DC, Koteliansky VE, Wang SS, and Bissell DM. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 127: 2037-2048, 1994[Abstract].

32.   Kornblihtt, AR, Umezawa K, Vibe-Pedersen K, and Baralle FE. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J 4: 1755-1759, 1985[Abstract].

33.   Laemmli, UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970[ISI][Medline].

34.   Laitinen, L, Vartio T, and Virtanen I. Cellular fibronectins are differentially expressed in human fetal and adult kidney. Lab Invest 64: 492-498, 1991[ISI][Medline].

35.   Magnuson, VL, Young M, Schattenberg DG, Mancini MA, Chen D, Steffensen B, and Klebe RJ. The alternative splicing of fibronectin pre-mRNA is altered during aging and in response to growth factors. J Biol Chem 266: 14654-14662, 1991[Abstract/Free Full Text].

36.   Malis, CD, Cheung JY, Leaf A, and Bonventre JV. Effects of verapamil in models of ischemic acute renal failure in the rat. Am J Physiol Renal Fluid Electrolyte Physiol 245: F735-F742, 1983[Abstract/Free Full Text].

37.   Mathews, GA, and Ffrench-Constant C. Embryonic fibronectins are up-regulated following peripheral nerve injury in rats. J Neurobiol 26: 171-188, 1995[ISI][Medline].

38.   McLean, IW, and Nakane PK. Periodate-lysine-paraformaldehyde fixative. A new fixative for electron microscopy. J Histochem Cytochem 22: 1077-1083, 1974[ISI][Medline].

39.   Mendrick, DL, Chung DC, and Rennke HG. Heymann antigen gp330 demonstrates affinity for fibronectin, laminin, and type I collagen and mediates rat proximal tubule epithelial cell adherence to such matrices in vitro. Exp Cell Res 188: 23-35, 1990[ISI][Medline].

40.   Mosher, DF. Fibronectin. New York: Academic, 1989.

41.   Nickeleit, V, Kaufman AH, Zagachin L, Dutt JE, Foster CS, and Colvin RB. Healing corneas express embryonic fibronectin isoforms in the epithelium, subepithelial stroma, and endothelium. Am J Pathol 149: 549-558, 1996[Abstract].

42.   Nickeleit, V, Zagachin L, Nishikawa K, Peters JH, Hynes RO, and Colvin RB. Embryonic fibronectin isoforms are synthesized in crescents in experimental autoimmune glomerulonephritis. Am J Pathol 147: 965-978, 1995[Abstract].

43.   Norton, PA, and Hynes RO. Alternative splicing of chicken fibronectin in embryos and in normal and transformed cells. Mol Cell Biol 7: 4297-4307, 1987[ISI][Medline].

44.   Pagani, F, Zagato L, Vergani C, Casari G, Sidoli A, and Baralle FE. Tissue-specific splicing pattern of fibronectin messenger RNA precursor during development and aging in rat. J Cell Biol 113: 1223-1229, 1991[Abstract].

45.   Paul, JI, Schwarzbauer JE, Tamkun JW, and Hynes RO. Cell type-specific fibronectin subunits generated by alternative splicing. J Biol Chem 261: 12258-12265, 1986[Abstract/Free Full Text].

46.   Peters, JH, Chen G, and Hynes RO. Fibronectin isoform distribution in the mouse. II Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments of the adult mouse. Cell Adhes Commun 4: 127-148, 1996[ISI][Medline].

47.   Peters, JH, and Hynes RO. Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. Cell Adhes Commun 4: 103-125, 1996[ISI][Medline].

48.   Racusen, LC, Fivush BA, Li YL, Slatnik I, and Solez K. Dissociation of tubular cell detachment and tubular cell death in clinical and experimental "acute tubular necrosis." Lab Invest 64: 546-556, 1991[ISI][Medline].

49.   Rappolee, DA, Mark D, Banda MJ, and Werb Z. Wound macrophages express TGF-beta and other growth factors in vivo: analysis by mRNA phenotyping. Science 241: 708-712, 1988[ISI][Medline].

50.   Reimer, KA, Ganote CE, and Jennings RB. Alterations in renal cortex following ischemic injury. III. Ultrastructure of proximal tubule after ischemia or autolysis. Lab Invest 26: 347-363, 1972[ISI][Medline].

51.   Schwarzbauer, JE. Alternative splicing of fibronectin: three variants, three functions. Bioessays 13: 527-533, 1991[ISI][Medline].

52.   Schwarzbauer, JE. The fibronectin gene. In: Extracellular Matrix Genes, edited by Sandell LJ, and Boyd CD.. San Diego, CA: Academic, 1990, p. 195-219.

53.   Schwarzbauer, JE, Patel RS, Fonda D, and Hynes RO. Multiple sites of alternative splicing of the rat fibronectin gene transcript. EMBO J 6: 2573-2580, 1987[Abstract].

54.   Schwarzbauer, JE, Paul JI, and Hynes RO. On the origin of species of fibronectin. Proc Natl Acad Sci USA 82: 1424-1428, 1985[Abstract].

55.   Schwarzbauer, JE, Spencer CS, and Wilson CL. Selective secretion of alternatively spliced forms of rat fibronectin. J Cell Biol 109: 3445-3453, 1989[Abstract].

56.   Schwarzbauer, JE, Tamkun JW, Lemischka IR, and Hynes RO. Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 35: 421-431, 1983[ISI][Medline].

57.   Serini, G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, and Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta 1. J Cell Biol 142: 873-881, 1998[Abstract/Free Full Text].

58.   Sharma, K, and Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol Renal Fluid Electrolyte Physiol 266: F829-F842, 1994[Abstract/Free Full Text].

59.   Sutton, TA, and Molitoris BA. Mechanisms of cellular injury in ischemic acute renal failure. Semin Nephrol 18: 490-497, 1998[ISI][Medline].

60.   Takasaki, I, Chobanian AV, Mamuya WS, and Brecher P. Hypertension induces alternatively spliced forms of fibronectin in rat aorta. Hypertension 20: 20-25, 1992[Abstract].

61.   Tamkun, JW, and Hynes RO. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem 258: 4641-4647, 1983[Abstract/Free Full Text].

62.   Thadhani, R, Pascual M, and Bonventre JV. Acute renal failure. N Engl J Med 334: 1448-1460, 1996[Free Full Text].

63.   Torras, J, Cruzado JM, Riera M, Condom E, Duque N, Herrero I, Merlos M, Espinosa L, Lloberas N, Egido J, and Grinyo JM. Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. Kidney Int 56: 1798-1808, 1999[ISI][Medline].

64.   Vartio, T, Laitinen L, Narvanen O, Cutolo M, Thornell LE, Zardi L, and Virtanen I. Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci 88: 419-430, 1987[Abstract].

65.   Venkatachalam, MA, Bernard DA, Donohoe JF, and Levinsky NG. Ischemic damage and repair in the rat proximal tubule: differences among the S1, S2, and S3 segments. Kidney Int 14: 31-49, 1978[ISI][Medline].

66.   Viedt, C, Burger A, and Hansch GM. Fibronectin synthesis in tubular epithelial cells: up-regulation of the EDA splice variant by transforming growth factor beta . Kidney Int 48: 1810-1817, 1995[ISI][Medline].

67.   Vitale, AT, Pedroza-Seres M, Arrunategui-Correa V, Lee SJ, DiMeo S, Foster CS, and Colvin RB. Differential expression of alternatively spliced fibronectin in normal and wounded rat corneal stroma vs. epithelium. Invest Ophthalmol Vis Sci 35: 3664-3672, 1994[Abstract].

68.   Vogelezang, MG, Scherer SS, Fawcett JW, and Ffrench-Constant C. Regulation of fibronectin alternative splicing during peripheral nerve repair. J Neurosci Res 56: 323-333, 1999[ISI][Medline].

69.   Wagner, MC, and Molitoris BA. Renal epithelial polarity in health and disease. Pediatr Nephrol 13: 163-170, 1999[ISI][Medline].

70.   Walker, PD. Alterations in renal tubular extracellular matrix components after ischemia-reperfusion injury to the kidney. Lab Invest 70: 339-346, 1994[ISI][Medline].

71.   Wennerberg, K, Lohikangas L, Gullberg D, Pfaff M, Johansson S, and Fassler R. beta 1 integrin-dependent and -independent polymerization of fibronectin. J Cell Biol 132: 227-238, 1996[Abstract].

72.   Witzgall, R, Brown D, Schwarz C, and Bonventre JV. Localization of proliferating cell nuclear antigen, vimentin, c-fos, and clusterin in the postischemic kidney. J Clin Invest 93: 2175-2188, 1994[ISI][Medline].

73.   Wu, C, Bauer JS, Juliano RL, and McDonald JA. alpha 5beta 1 Integrin fibronectin receptor, but not the alpha 5 cytoplasmic domain, functions in an early and essential step in fibronectin matrix assembly. J Biol Chem 268: 21883-21888, 1993[Abstract/Free Full Text].

74.   Wu, C, Keivens VM, O'Toole TE, McDonald JA, and Ginsberg MH. Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Cell 83: 715-724, 1995[ISI][Medline].

75.   Yamamoto, T, Noble NA, Miller DE, and Border WA. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45: 916-927, 1994[ISI][Medline].

76.   Zuk, A, Bonventre JV, Brown D, and Matlin KS. Polarity, integrin and extracellular matrix dynamics in the postischemic rat kidney. Am J Physiol Cell Physiol 275: C711-C731, 1998[Abstract].


Am J Physiol Renal Fluid Electrolyte Physiol 280(6):F1037-F1053
0363-6127/01 $5.00 Copyright © 2001 the American Physiological Society